Pathophysiology and Reactivation of Varicella-Zoster Virus
Shingles, medically termed herpes zoster, is a neurocutaneous disease resulting from the reactivation of the varicella-zoster virus (VZV), the same double-stranded DNA virus that causes chickenpox (varicella) during primary infection. Following the resolution of chickenpox, VZV migrates retrograde along sensory nerves to establish a lifelong latent infection in the cranial nerve and dorsal root ganglia. Under the influence of declining cell-mediated immunity—often due to aging, immunosuppressive therapy, or systemic illness—the virus reactivates. It replicates within the ganglion, causing neuronal necrosis and severe inflammation, and then travels anterograde down the sensory nerve fibers to the skin. This leads to the characteristic unilateral dermatomal vesicular eruption, which is typically accompanied by intense, localized neuropathic pain.
Clinical Stages and Diagnostic Recognition
The clinical course of herpes zoster generally progresses through three distinct phases:
- Prodromal Phase: Patients often experience burning, tingling, itching, or hyperesthesia in the affected dermatome 1 to 5 days before the rash appears. This prodromal pain can be severe and may mimic cardiac pain (thoracic dermatomes) or acute abdomen (abdominal dermatomes).
- Acute Eruptive Phase: Characterized by the appearance of erythematous macules and papules that quickly evolve into clusters of clear vesicles along a single dermatome (most commonly thoracic or trigeminal). The lesions are strictly unilateral and do not cross the anatomical midline. Over 7 to 10 days, these vesicles pustulate, rupture, and form crusts.
- Chronic Phase (Postherpetic Neuralgia): Defined as neuropathic pain persisting for more than 90 days after the onset of the rash. Postherpetic Neuralgia (PHN) is the most common debilitating complication of herpes zoster, characterized by constant burning, intermittent lancinating pain, and severe allodynia (pain triggered by non-painful stimuli, such as clothing touching the skin).
💡 💡 Hutchinson’s Sign and Ophthalmic Referrals
Clinicians must closely examine the face of patients with trigeminal shingles. Hutchinson’s sign—the presence of shingles vesicles on the tip, side, or root of the nose—indicates involvement of the nasociliary branch of the ophthalmic nerve (CN V1). This is a strong predictor of ophthalmic complications, requiring immediate ophthalmological evaluation to prevent corneal scarring and vision loss.
Antiviral Therapy and the 72-Hour Window
For patients presenting with acute herpes zoster, systemic antiviral therapy is the standard of care. First-line agents include oral valacyclovir (1000 mg three times daily) or famciclovir (500 mg three times daily) for 7 days. These acyclovir prodrugs have superior bioavailability and require less frequent dosing than oral acyclovir. To achieve maximum efficacy, antiviral therapy should be initiated within 72 hours of rash onset. Early initiation has been shown to accelerate lesion healing, reduce the duration of viral shedding, and decrease the severity and duration of acute and chronic neuropathic pain. Antiviral therapy is also indicated after 72 hours if new vesicles are actively forming or in patients who are elderly, immunocompromised, or experiencing severe ophthalmic involvement.
Preventive Vaccination: The Shingrix Advantage
Preventative strategies are essential for reducing the burden of herpes zoster and its complications. The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) recommend the Recombinant Zoster Vaccine (RZV, brand name Shingrix) as the preferred vaccine. Shingrix is a non-live, recombinant subunit vaccine containing VZV glycoprotein E combined with a novel adjuvant system (AS01B). It is indicated as a two-dose series (administered 2 to 6 months apart) for immunocompetent adults aged 50 years and older, and for immunocompromised adults aged 19 years and older. Clinical trials have demonstrated that Shingrix provides greater than 90% protection against shingles and PHN across all age groups, outperforming the older, live-attenuated vaccine (Zostavax), which is no longer available in many countries. If shingles occurs in patients with pre-existing skin barrier dysfunction, such as eczema (atopic dermatitis), secondary bacterial infections can complicate the clinical picture, emphasizing the importance of vaccination.
Management of Postherpetic Neuralgia (PHN)
When PHN develops, treatment focuses on symptom control and improving quality of life. Pharmacological options include:
- Gabapentinoids: Gabapentin and pregabalin bind to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
- Tricyclic Antidepressants (TCAs): Amitriptyline and nortriptyline inhibit norepinephrine and serotonin reuptake, enhancing descending pain-inhibitory pathways. Use with caution in elderly patients due to anticholinergic side effects.
- Topical Agents: Lidocaine patches (5%) or capsaicin patches (8%) offer targeted, localized pain relief with minimal systemic side effects.
💡 Frequently Asked Questions (FAQ)
Q1: Can you catch shingles from someone who has shingles or chickenpox?
A1: You cannot “catch” shingles directly. Shingles is a reactivation of your own latent virus. However, a person with active shingles vesicles can transmit VZV via direct contact to someone who has never had chickenpox or the varicella vaccine. The exposed person would develop chickenpox, not shingles.
Q2: Why is the Shingrix vaccine preferred over the older Zostavax?
A2: Shingrix is a recombinant, non-live vaccine that provides over 90% efficacy against shingles and PHN, and its protection remains high for years. The older Zostavax was a live-attenuated vaccine with lower efficacy (around 51%) that declined significantly over time and could not be given to immunocompromised patients.
Q3: Can you get shingles more than once?
A3: Yes, recurrent episodes of herpes zoster can occur, particularly in immunocompromised individuals or as cell-mediated immunity declines with advanced age. Receiving the Shingrix vaccine is recommended even if you have already had shingles to prevent future recurrences.
📚 References & Sources
- Dooling, K. L., et al. (2018). Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Recommendations and Reports, 67(1), 1-11.
- Cohen, J. I. (2013). Herpes Zoster. New England Journal of Medicine, 369(3), 255-263.